StockNews.com Initiates Coverage on Evogene (NASDAQ:EVGN)

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued to investors on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital reduced their price target on Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 23rd.

Evogene Price Performance

Evogene stock opened at $1.43 on Wednesday. The company has a market cap of $7.68 million, a price-to-earnings ratio of -0.32 and a beta of 1.36. The firm has a 50-day moving average of $2.15 and a 200-day moving average of $4.07. Evogene has a one year low of $1.40 and a one year high of $10.40.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC acquired a new stake in Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is currently owned by hedge funds and other institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.